

Material Information (3176 MEDIGEN?????)SEQ_NO 1Date of announcement 2025/02/02Time of announcement 16:01:23Subject

Reporting the Result of PI-initiated Phase I
Clinical Trial for OBP-301-Chemoradiation Combination
Therapy in ASCO (Corrected)

Date of events 2025/01/30To which item it meetsparagraph 53Statement

1.Date of occurrence of the event:2025/01/30

2.Company name:Medigen Biotechnology Corp.

3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office

4.Reciprocal shareholding ratios:N/A

5.Cause of occurrence:

Medigen Biotechnology Corp. and the Japanese publicly traded company
Oncolys BioPharma ("Oncolys", TSE stock code 4588), are jointly
developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys
issued a correction on January 30, 2025, regarding its January 24, 2025,
announcement. The correction pertains to the reported number of recruited
patients and the terms of safety assessment of the investigator-initiated
Phase I clinical trial for OBP-301 in combination with chemoradiation in
esophageal or gastro-esophageal cancer conducted in the United States,
reported its results at the American Society of Clinical Oncology (ASCO)
Gastrointestinal Cancers Symposium. The wording in the January 24, 2025,
announcement under (2) Results of the Study, A. Safety Assessment has been
corrected. The original statement, "Among the 14 participants who
completed the trial complying with the protocol treatment, the most common
treatment-related serious or life-threatening adverse events..." has been
revised to "Among the 15 participants recruited, the most common
treatment-related serious or life-threatening adverse events...".

6.Countermeasures:none

7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):

(1)The development timeline for new drugs is long, the investment costs are
high, and success is not guaranteed. These factors may pose risks to
investors, who should make careful judgments and invest cautiously.

(2)Our company shares the development costs of OBP-301 with Japan's Oncolys
and will share in the future commercial benefits.

(3)Link to the announcement from Japan's Oncolys:

<https://ssl4.eir-parts.net/doc/4588/tdnet/2553160/00.pdf>